📅 PUBMED DAILY TRIAGE — 2026-05-08
Window: 2026-05-07T09:00:00Z → 2026-05-08T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~88 candidates | Candidates evaluated: 71 kept for scoring High priority: 12 | Standard: 10 | Low/archive: ~30 discarded | Unsolicited finds: 1 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk
TR-2026-05-08-001 · PMID 42095149 · SGLT2i + conventional therapy in myocardial infarction: meta-analysis of 13 RCTs · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE → Meta-analysis of 13 RCTs (n=22,238) demonstrates SGLT2i reduce post-MI HF hospitalization by 24% (RR=0.76), MACE by 16% (RR=0.84), and improve LVEF (+3.45%) — benefit independent of diabetes status, directly supporting guideline expansion for post-MI SGLT2i use.
TR-2026-05-08-008 · PMID 42098477 · Epidemiology of cardiovascular-kidney-metabolic syndrome (Nat Rev Nephrol) · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE → Nature Reviews Nephrology comprehensive CKM epidemiology review: most adults already at stage ≥1 CKM; GLP-1 RAs, SGLT2i, and non-steroidal MRAs offer multisystem benefits; cost/access barriers highlighted; GLP-1/SGLT2 watchlist core coverage.
TR-2026-05-08-009 · PMID 42092956 · CVOT Summit 2025 Report (Cardiovasc Diabetol, 60+ experts) · 8/10 🟠 NOVEL_TREATMENT → Annual CVOT summit highlights: first head-to-head CVOT (SURPASS-CVOT), finerenone+empagliflozin combination (CONFIDENCE), oral GLP-1 RA orforglipron (ATTAIN-1), and novel aldosterone synthase inhibitor baxdrostat (BaxHTN) — comprehensive 2025 CKM therapeutic landscape update.
Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)
TR-2026-05-08-002 · PMID 42098138 · Pancreatic cancer (Nature Reviews Disease Primers, 18 authors) · 8/10 🔴 EARLY_CANCER_DETECTION → Landmark NatRevDisPrimers from MSK, DKFZ, Hopkins, Oxford (18 experts): RNA vaccines and KRAS-directed agents as emerging molecular frontiers; AI-assisted imaging and liquid biopsy advancing for early detection and risk-adapted surveillance — 2026's definitive pancreatic cancer reference.
TR-2026-05-08-003 · PMID 42095156 · Radiogenomic CT radiomics + ctDNA in advanced NSCLC (prospective, n=91, IEO Milan) · 8/10 🔴 EARLY_CANCER_DETECTION → Prospective study: integrating CT radiomics with plasma ctDNA (85% concordance vs tissue) achieves DFS C-index 0.77 vs 0.59 clinical-only, with 0.80 in EGFR-mutant subset; longitudinal ctDNA clearance correlated with treatment response in 17/21 patients — strong multi-modal liquid biopsy framework.
TR-2026-05-08-004 · PMID 42094766 · Self-collected menstrual blood HPV testing meta-analysis (n=1,672) · 8/10 🔴 EARLY_CANCER_DETECTION → Meta-analysis (7 studies, n=1,672): self-collected menstrual blood for HPV testing shows sensitivity 0.96 for CIN/cervical cancer detection; low specificity (0.53) suitable for first-tier screening; novel self-sampling approach with major access implications for cervical cancer prevention.
TR-2026-05-08-006 · PMID 42097707 · HIV care + cervical cancer screening post-conflict Tigray (BMJ Global Health, n=2,515) · 8/10 🟡 UNDERSERVED_POPULATION → Multidomain cohort: despite Tigray war health system collapse, MTCT fell from 5.56% (2022) to 0% (2025); 98.3% cervical cancer screening acceptance; cascade completion 76.9% — remarkable post-conflict HIV + cancer screening recovery data in high-unmet-need population.
Hematologic Malignancies
TR-2026-05-08-007 · PMID 42096665 · Modern Management of Mantle Cell Lymphoma (ASCO Educ Book, MSK/LMU/Oxford) · 8/10 🟠 NOVEL_TREATMENT → ASCO Educational Book consensus review from leading MCL centers: BTKi integration into frontline therapy may limit ASCT to high-risk subsets; CAR-T and bispecific antibodies reshaping R/R MCL; TP53-mutant MCL may benefit from targeted triplets — guideline-proximal management update.
Rare Diseases with High Unmet Need
TR-2026-05-08-005 · PMID 42097909 · ECFS statement on CF CFTR theratyping/theranostics (J Cyst Fibros, 16 experts) · 8/10 🟡 UNDERSERVED_POPULATION → European CF Society consensus (16 experts): advocates functional assay-based access (intestinal organoids, nasal epithelial cells) to ETI/VTD for CF patients with rare/ultrarare CFTR variants not covered by genotype-based approvals — major policy statement addressing equity gap in CF rare variant populations.
TR-2026-05-08-010 · PMID 42092697 · Lipidomics in familial partial lipodystrophy type 2 (n=115+289, Baker Institute) · 8/10 🟡 UNDERSERVED_POPULATION → Case-control lipidomics (787 species, n=115 FPLD2 + 289 controls): elevated ceramides/TGs and reduced plasmalogens mirror T2DM signature; mBMI tool identifies metabolic risk in FPLD2 patients with normal BMI — rare disease with high metabolic unmet need, novel biomarker utility.
Aging, Longevity, and Population Health
TR-2026-05-08-011 · PMID 42096201 · Biomarkers, cognition, and mortality in centenarians (JAMA Netw Open, n=495, 17yr) · 8/10 ⚪ PROMISING_PRELIMINARY → Population cohort of 495 centenarians (17-year follow-up): plasma NfL — not Aβ42/40 or p-tau181 — is the dominant biomarker for both cognitive impairment and all-cause mortality (HR 1.36) in extreme aging, suggesting neurodegeneration rather than amyloid pathology drives longevity outcomes at the century mark.
💡 UNSOLICITED FINDS (Sentinel Scan)
TR-2026-05-08-012 · PMID 42094248 · AHDM invasive hemodynamic monitoring in shock meta-analysis (n=636,441) · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE (unsolicited_find) → Systematic review + meta-analysis (34 studies, n=636,441): advanced hemodynamic monitoring reduces in-hospital mortality 34% in any shock (OR 0.66) and 32% in cardiogenic shock via PAC-guided therapy (OR 0.68); PROSPERO-registered, Semmelweis University; impressive dataset outside core watchlist.
🟢⚪ STANDARD (5-7) — Top by Topic
Hematologic Malignancies
- TR-2026-05-08-013 · PMID 42094005 · Ph+ ALL chemotherapy-free future: evolution of TKI + immunotherapy (review) · 7/10 · Treatment Innovation
- TR-2026-05-08-014 · PMID 42096681 · HLH new grading classification + targeted therapies (emapalumab, ruxolitinib, tocilizumab) · 7/10 · Treatment Innovation
- PMID 42093982 (CAR-T exhaustion NHL, Front Immunol, mechanisms review) · 6/10 · Treatment Innovation
- PMID 42098093 (AML CD84 novel CAR-T target, Nat Commun, preclinical, cap=5) · 5/10 · Treatment Innovation
- PMID 42095505 (FL NQO1 NADH nanoplatform, murine model, preclinical, cap=5) · 5/10 · Drug Development
CBC-Based Diagnostics and ML in Hematology
- TR-2026-05-08-021 · PMID 42098419 · PICC-CRBSI ML (random forest AUC 0.973) in preterm NICU, WBC/CRP key SHAP features · 6/10 · Diagnostics
- TR-2026-05-08-020 · PMID 42092706 · β-thalassemia MCV/MCHC + SyMRI brain microstructure cognitive link · 6/10 · Diagnostics
Early Cancer Detection
- PMID 42098393 (Liquid biopsy CNS tumors comprehensive review, CSF ctDNA IDH/H3K27M) · 6/10 · Diagnostics
- PMID 42097193 (CTCs isolation/characterization review, AI-enhanced, Clin Chim Acta) · 6/10 · Diagnostics
- TR-2026-05-08-017 · PMID 42094290 · Single-session PCCT coronary+carotid+lung screening (n=172, ACTA study) · 7/10 · Diagnostics
AI/ML in Clinical Diagnostics and Imaging
- TR-2026-05-08-016 · PMID 42097285 · AI cancer diagnostics primer (JNCI, NCI group, digital pathology + liquid biopsy) · 7/10 · Diagnostics
- PMID 42092679 (AI OCT/OCTA diabetic retinopathy systematic review, 175 studies, AUC 0.90-0.99) · 7/10 · Diagnostics
Precision Oncology and Genomic Medicine
- PMID 42098138 (counted in Early Cancer Detection as HIGH)
- PMID 42097035 (NOS2/COX2 spatial CD8+ T cell landscape ER-breast cancer, NCI/Redox Biol) · 7/10 · Genomics/Precision Medicine
Novel Therapeutics
- TR-2026-05-08-018 · PMID 42093995 · TNBC tumor-associated lymphangiogenesis + immunotherapy systematic review (59 studies) · 7/10 · Treatment Innovation
- PMID 42096621 (Uterine sarcomas clinical management + targeted/immunotherapy review, Obstet Gynecol Surv) · 7/10 · Treatment Innovation
- PMID 42094000 (Tissue-resident memory T cells dual role in tumors + autoimmunity, review) · 6/10 · Treatment Innovation
Cardiovascular-Metabolic
- TR-2026-05-08-019 · PMID 42095067 · GLP-1 RAs obesity + IBD systematic review (n≤47,424, 7 studies) · 6/10 · Drug Development
- PMID 42095180 (Pericoronary FAI + TyG index in CMM/T2DM, n=497, C-stat 0.900 for CMM) · 6/10 · Diagnostics
Aging, Longevity, and Population Health
- TR-2026-05-08-015 · PMID 42096199 · Circadian rest-activity rhythms + epigenetic age acceleration (JAMA Netw Open, n=207) · 7/10 · Diagnostics
- TR-2026-05-08-022 · PMID 42095817 · Cellular senescence: precision anti-aging interventions, "prevention-first" paradigm · 6/10 · Treatment Innovation
Rare Diseases
- PMID 42095135 (Werner syndrome WRN-108 ASO exon skipping, preclinical rat/monkey, cap=5) · 5/10 · Drug Development
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 7 articles
- Diagnostics: 8 articles
- Early Detection: 5 articles
- Drug Development: 3 articles
- Genomics/Precision Medicine: 2 articles
- Public Health: 2 articles
- Other: 1 article (unsolicited)
By evidence maturity:
- Potentially Practice-Changing: 3
- Validated: 10
- Exploratory: 9
By watchlist topic (reviewed / kept ≥5 / highest score):
| Topic | Reviewed | Kept | High | Best Score |
|---|---|---|---|---|
| Hematologic malignancies | 10 | 7 | 1 | 8 (PMID 42096665) |
| CBC/ML hematology | 2 | 2 | 0 | 6 — 16th consecutive empty HIGH |
| Early cancer detection | 10 | 8 | 4 | 8 |
| AI/ML diagnostics | 7 | 5 | 0 | 7 |
| Precision oncology | 8 | 5 | 1 | 8 (counted in ECD) |
| Novel therapeutics | 9 | 5 | 0 | 7 |
| Cardiovascular-metabolic | 8 | 6 | 3 | 8 (PMID 42095149) |
| Aging/longevity | 9 | 4 | 1 | 8 (PMID 42096201) |
| Rare diseases | 8 | 5 | 2 | 8 |
| Sentinel | 8 | 4 | 1 | 8 (PMID 42094248) |
By source type: peer_reviewed 22 | preprint 0
Topics with zero 8+ articles this run: CBC/ML hematology (16th consecutive), AI/ML diagnostics, Novel therapeutics (standalone)
🔧 RUN NOTES
- Window: 2026-05-07T09:00:00Z → 2026-05-08T09:00:00Z (CRDT, incremental, no expansion triggered)
- Aging/longevity humans[MeSH] filter: Continued to perform well; 61 raw results retrieved with manageable noise.
- CBC/ML hematology: Only 2 results in window (both relevant STANDARD). The 5-result expansion threshold was not triggered in terms of watchlist-relevant articles since both found articles were scored. 16th consecutive zero HIGH window for this topic.
- Cardiovascular-metabolic outstanding day: Best window in recent memory — 3 HIGH articles including the SGLT2i+MI meta-analysis (n=22,238) which is the strongest single evidence point of the run.
- Novel therapeutics: Despite 181 raw results, no HIGH articles — window dominated by basic science reviews, small preclinical studies, and non-core immunology reviews.
- Deduplication: PMID 42093982 appeared in both hematologic and novel therapeutics topic queries; counted once with dual matched topics. PMID 42098138 appeared in both early cancer detection and precision oncology queries; counted once.
- Preclinical cap applied: PMID 42098093 (Nat Commun AML CD84 CAR-T) capped at 5/10 per policy; PMID 42095135 (Werner syndrome ASO) capped at 5/10; PMID 42095505 (FL nanoplatform) capped at 5/10.
- Alert dispatch: 5 Telegram alerts sent to 6712950583 (max per run).
- Rolling 7-day pattern (from state): CBC/ML hematology: 16 consecutive zero-HIGH runs; Novel therapeutics: consistently produces STANDARD but rarely HIGH in recent windows; Cardiovascular-metabolic: intermittent HIGH with today's exceptional yield (3 HIGH).